Literature DB >> 16942587

Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: A landmark national US survey.

S Kaplan1, M Naslund.   

Abstract

This US national survey evaluated beliefs and attitudes towards the enlarged prostate (EP) and its treatment among the men of a national sample aged > or =50 years in the US (400 with and 700 without EP), and a national sample of 100 primary care doctors and 100 urologists. The principal risk of EP was considered to be acute urinary retention among the majority of physicians, while the majority of patients believed it to be prostate cancer. In contrast to physicians' beliefs, the majority of patients with moderate-to-severe symptoms are more concerned with long-term effects of EP than acute symptoms. Furthermore, they are willing to wait up to 3 months for symptom relief if treatment of the underlying condition is achieved. Doctors and patients agree that most patients want to avoid surgery but only 18% of surgery patients were told about drugs that could reduce the risk of surgery. These findings demonstrate significant differences between the beliefs and attitudes of patients and physicians towards EP.

Entities:  

Mesh:

Year:  2006        PMID: 16942587     DOI: 10.1111/j.1742-1241.2006.01129.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  7 in total

1.  Patient's and physician's behavior on the management of benign prostatic hyperplasia among the patients at the risk of clinical progression. A multicenter noninterventional trial in Slovakia by "Prostate and Expectations of Treatment: Epidemiology Research" (PETER) study group.

Authors:  Peter Weibl; Peter Laurinc; Roman Tomaškin; Tobias Klatte; Shahrokh Shariat F; Miroslav Helbich; Danica Fačkovcova; Peter Bujdák
Journal:  Wien Klin Wochenschr       Date:  2015-03-28       Impact factor: 1.704

Review 2.  Dutasteride: a review of its use in the management of prostate disorders.

Authors:  Susan J Keam; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey.

Authors:  Phillip Ertel; Burkay Adalig; Ipek Demircan; Belinda Lartey; Michael J Manyak
Journal:  Int J Clin Pract       Date:  2016-10       Impact factor: 2.503

4.  Men's preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment.

Authors:  Colette Mankowski; Divine Ikenwilo; Sebastian Heidenreich; Mandy Ryan; Jameel Nazir; Cathy Newman; Verity Watson
Journal:  Patient Prefer Adherence       Date:  2016-11-24       Impact factor: 2.711

5.  Perspective on the Rezūm® System: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy.

Authors:  Henry H Woo; Ricardo R Gonzalez
Journal:  Med Devices (Auckl)       Date:  2017-04-27

6.  Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey.

Authors:  M Emberton; M Marberger; J de la Rosette
Journal:  Int J Clin Pract       Date:  2007-11-19       Impact factor: 2.503

7.  Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  James C Ulchaker; Melissa S Martinson
Journal:  Clinicoecon Outcomes Res       Date:  2017-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.